Regeneron Announces Upcoming Investor Conference Presentations

TARRYTOWN, N.Y., April 23, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations as follows:

• J.P. Morgan 2018 Spring Biotech Conference Call Series at 10:00 a.m. Eastern Time on Tuesday, May 8, 2018
• Bank of America Merrill Lynch 2018 Healthcare Conference at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) on Wednesday, May 16, 2018
• Barclays 2018 Biopharmaceuticals CEO/CFO Conference Call Series at 11:00 a.m. Eastern Time on Friday, June 1, 2018

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events.cfm.  Replays of the conference calls and webcasts will be archived on the Company's website and will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

View original content:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-presentations-300633878.html

SOURCE Regeneron Pharmaceuticals, Inc.